Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia

por Eiring, Anna M, Deininger, Michael W
Publicado 2014

Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia

por Ribeiro, Sara, Eiring, Anna M., Khorashad, Jamshid S.
Publicado 2021

P-160: Disparities in multiple myeloma between hispanics and non-hispanics – real world outcomes

por Shaikh, Hira, Nhim, Vutha, Bencomo-Alvarez, Alfonso, Eiring, Anna
Publicado 2022

Advances in the treatment of chronic myeloid leukemia

por Eiring, Anna M, Khorashad, Jamshid S, Morley, Kimberly, Deininger, Michael W
Publicado 2011

Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics

por Le, Ilene, Dhandayuthapani, Subramanian, Chacon, Jessica, Eiring, Anna M., Gadad, Shrikanth S.
Publicado 2022

Blood cancer health disparities in the United States Hispanic population

por Bencomo-Alvarez, Alfonso E., Rubio, Andres J., Gonzalez, Mayra A., Eiring, Anna M.
Publicado 2021

A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia

por Bolandi, Seyed Mohammadreza, Pakjoo, Mahdi, Beigi, Peyman, Kiani, Mohammad, Allahgholipour, Ali, Goudarzi, Negar, Khorashad, Jamshid S., Eiring, Anna M.
Publicado 2021

26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy

por Rubio, Andres J., Bencomo-Alvarez, Alfonso E., Young, James E., Velazquez, Vanessa V., Lara, Joshua J., Gonzalez, Mayra A., Eiring, Anna M.
Publicado 2021

A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia

por Woessner, David W., Eiring, Anna M., Bruno, Benjamin J., Zabriskie, Matthew S., Reynolds, Kimberly R., Miller, Geoffrey D., O’Hare, Thomas, Deininger, Michael W., Lim, Carol S.
Publicado 2015

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

por Patel, Ami B., Pomicter, Anthony D., Yan, Dongqing, Eiring, Anna M., Antelope, Orlando, Schumacher, Jonathan A., Kelley, Todd W., Tantravahi, Srinivas K., Kovacsovics, Tibor J., Shami, Paul J., O’Hare, Thomas, Deininger, Michael W.
Publicado 2020

The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer

por Tychhon, Boranai, Allen, Jesse C., Gonzalez, Mayra A., Olivas, Idaly M., Solecki, Jonathan P., Keivan, Mehrshad, Velazquez, Vanessa V., McCall, Emily B., Tapia, Desiree N., Rubio, Andres J., Jordan, Connor, Elliott, David, Eiring, Anna M.
Publicado 2023

RAPID CONVERSION OF CHRONIC MYELOID LEUKEMIA TO CHRONIC MYELOMONOCYTIC LEUKEMIA IN A PATIENT ON IMATINIB THERAPY

por Khorashad, Jamshid S., Tantravahi, Srinivas K., Yan, Dongqing, Mason, Clinton C., Qiao, Yi, Eiring, Anna M., Gligorich, Keith, Hein, Than, Pomicter, Anthony D., Reid, Alistair G., Kelley, Todd W., Marth, Gabor T., O'Hare, Thomas, Deininger, Michael W.
Publicado 2016

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

por Eiring, Anna M., Khorashad, Jamshid S., Anderson, David J., Yu, Fan, Redwine, Hannah M., Mason, Clinton C., Reynolds, Kimberly R., Clair, Phillip M., Gantz, Kevin C., Zhang, Tian Y., Pomicter, Anthony D., Kraft, Ira L., Bowler, Amber D., Johnson, Kara, Mac Partlin, Mary, O’Hare, Thomas, Deininger, Michael W.
Publicado 2015

Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B

por Bencomo-Alvarez, Alfonso E., Rubio, Andres J., Olivas, Idaly M., Gonzalez, Mayra A., Ellwood, Rebecca, Fiol, Carme Ripoll, Eide, Christopher A., Lara, Joshua J., Barreto-Vargas, Christian, Jave-Suarez, Luis F., Nteliopoulos, Georgios, Reid, Alistair G., Milojkovic, Dragana, Druker, Brian J., Apperley, Jane, Khorashad, Jamshid S., Eiring, Anna M.
Publicado 2021

19S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML)

por Lara, Joshua J., Bencomo-Alvarez, Alfonso E., Gonzalez, Mayra A., Olivas, Idaly M., Young, James E., Lopez, Jose L., Velazquez, Vanessa V., Glovier, Steven, Keivan, Mehrshad, Rubio, Andres J., Dang, Sara K., Solecki, Jonathan P., Allen, Jesse C., Tapia, Desiree N., Tychhon, Boranai, Astudillo, Gonzalo E., Jordan, Connor, Chandrashekar, Darshan S., Eiring, Anna M.
Publicado 2022

Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

por Eiring, Anna M., Page, Brent D. G., Kraft, Ira L., Mason, Clinton C., Vellore, Nadeem A., Resetca, Diana, Zabriskie, Matthew S., Zhang, Tian Y., Khorashad, Jamshid S., Engar, Alexander J., Reynolds, Kimberly R., Anderson, David J., Senina, Anna, Pomicter, Anthony D., Arpin, Carolynn C., Ahmad, Shazia, Heaton, William L., Tantravahi, Srinivas K., Todic, Aleksandra, Moriggl, Richard, Wilson, Derek J., Baron, Riccardo, O'Hare, Thomas, Gunning, Patrick T., Deininger, Michael W.
Publicado 2014

Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism

por Gonzalez, Mayra A., Olivas, Idaly M., Bencomo‐Alvarez, Alfonso E., Rubio, Andres J., Barreto‐Vargas, Christian, Lopez, Jose L., Dang, Sara K., Solecki, Jonathan P., McCall, Emily, Astudillo, Gonzalo, Velazquez, Vanessa V., Schenkel, Katherine, Reffell, Kelaiah, Perkins, Mariah, Nguyen, Nhu, Apaflo, Jehu N., Alvidrez, Efren, Young, James E., Lara, Joshua J., Yan, Dongqing, Senina, Anna, Ahmann, Jonathan, Varley, Katherine E., Mason, Clinton C., Eide, Christopher A., Druker, Brian J., Nurunnabi, Md, Padilla, Osvaldo, Bajpeyi, Sudip, Eiring, Anna M.
Publicado 2022